Press Releases

Elekta and Brainlab improve Interoperability and Treatment Capabilities in Stereotactic Neurosurgery Treatments

MADRID, September 29, 2016 – Elekta (EKTA-B.ST) and Brainlab announced today at the European Society of Stereotactic and Functional Neurosurgery (ESSFN) meeting in Madrid that they have entered into a technical exchange agreement regarding the new software from Brainlab, Elements Stereotaxy* and Elekta’s new precise delivery system, Leksell® Vantage™ Stereotactic System**.

To ensure a continuous evolution of interoperability and safety, Elekta and Brainlab have entered into a forward-looking technical exchange agreement that has the potential for more patients to benefit from powerful planning capabilities and accurate, safe treatments using Elekta and Brainlab equipment for stereotactic neurosurgical procedures.

This collaboration is designed to enable even smoother workflows and interoperability in stereotactic neurosurgical procedures when planning, accurately positioning devices in the brain, and verifying treatment using Elements and Leksell Vantage.

Based on Leksell Stereotactic System®, the gold standard within stereotactic neurosurgery, Leksell Vantage Stereotactic System, is the latest development from Elekta in the field of stereotactic neurosurgery. It now has a nonmetallic head frame for neuroimaging without compromise, enhanced patient comfort, and a new innovative arc design.

Elements Stereotaxy, in combination with Elements Automatic Segmentation, FiberTracking and post-operative Lead Localization**, are the latest additions to Brainlab’s product portfolio and together extend the advanced capabilities for planning as well as intra- and postoperative verification of the lead placement for stereotactic functional neurosurgery.

Visit our booths at ESSFN to find out more about the new products.

*This product is not available for sale and will not be available until all applicable approvals have been acquired.
** Leksell® Vantage™ Stereotactic System is not yet CE marked or 510(k) cleared and is not available for sale or distribution.

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,600 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on NASDAQ Stockholm. Website:

About Brainlab

Brainlab, headquartered in Munich, develops, manufactures and markets software-driven medical technology, enabling access to advanced, less invasive patient treatments.

Core products center on information-guided surgery, radiosurgery, precision radiation therapy, digital operating room integration, and information and knowledge exchange. Brainlab technology powers treatments in radiosurgery and radiotherapy as well as numerous surgical fields including neurosurgery, orthopedic, ENT, CMF, spine and trauma.

Privately held since its formation in Munich, Germany in 1989, Brainlab has more than 11,000 systems installed in about 100 countries. Brainlab employs 1,350 people in 19 offices worldwide, including 385 Research & Development engineers, who form a crucial part of the product development team.